{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.69"},{"groupId":"OG001","value":"15.38"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Stage III-IV aGVHD is defined as: Stage 0-3 skin, with Stage 2-3 liver, or Stage 2-3 GI; OR Stage 4 skin, liver or GI involvement.","groups":[{"description":"Conventional bone marrow transplant (BM)","id":"OG000","title":"Control BM Arm"},{"description":"G-CSF (filgrastim) stimulated bone marrow (G-BM)","id":"OG001","title":"Experimental G-BM Arm"}],"paramType":"NUMBER","populationDescription":"One patient is inevaluable and is excluded from analysis.","reportingStatus":"POSTED","timeFrame":"Up to 3 months","title":"Estimated Incidence of Grade III-IV Acute Graft-versus-host Disease (aGVHD)","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}